Lido Advisors
IBRX icon

Lido Advisors’s ImmunityBio IBRX Stock Holding History

Lido Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Sell
12,365
-1,419
-10% -$10.7K ﹤0.01% 2030
2026
Q1 		$106K Sell
13,784
-17,465
-56% -$120K ﹤0.01% 1850
2025
Q4 		$75.9K Hold
31,249
– – ﹤0.01% 1866
2025
Q3 		$76.9K Sell
31,249
-3,914
-11% -$10.1K ﹤0.01% 1776
2025
Q2 		$92.8K Buy
+35,163
New +$94.5K ﹤0.01% 1596

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lido Advisors's IBRX Position: Q2 2026 in Review

Lido Advisors reduced its ImmunityBio (IBRX) stake by 10% in Q2 2026, selling an estimated $10.7K and leaving 12,365 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Lido Advisors first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Lido Advisors held 12,365 shares of ImmunityBio worth $108K as of Q2 2026.
  • Lido Advisors sold 1,419 ImmunityBio shares in Q2 2026, an estimated $10.7K.
  • ImmunityBio made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #2030 holding.
  • Lido Advisors first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.